Lifecore has licensed the patented Corgel® BioHydrogel technology from the Cleveland Clinic. This biocompatible hyaluronan hydrogel is based on di-hydroxyphenyl linkages of tyramine substituted sodium hyaluronate (NaHy). Lifecore has completed ISO 10993 safety and toxicity studies on this technology.

Corgel® BioHydrogel has a wide range of physical properties depending on the tyramine substitution (TS) percentage and the tyramine substituted hyaluronan (TS-NaHy) concentration. Hydrogels formed from TS-NaHy solutions of 6.25 – 100 mg/mL display a spectrum of physical properties that include those of a weak gel, a paste, or a fractile solid.


  • Corgel® Kits are available with 1%, 3%, or 5% TS of the NaHy.
  • Depending on the targeted TS-NaHy concentration, Corgel® Kits yield a total of between 5 and 50mLs.

For more information, please see the Instructions for Proper Use.

>Download Corgel BioHydrogel Kit Instructions
>Download Detailed Chemistry Description

Hydrogel samples
Advantages of Corgel® BioHydrogel

Corgel® BioHydrogel can be formed under physiologic conditions. This allows for the direct inclusion of cells or bioactive agents prior to or during cross-linking. Alternatively, in situ cross-linking directly adjacent to living tissue can be done while maintaining cell and tissue viability. Because the degree of substitution required for using Corgel is very low (1% – 5%), much of the native sodium hyaluronate structure and behavior is maintained.

Both the functional groups, and the resulting cross-linked structures, have unique photometric properties that allow for evaluation of the degree of substitution and cross-linking.



  • Orthopedics
  • Regenerative medicine
  • Tissue engineering
  • Tissue/organ preservation
  • Urology
  • Vascular surgery
  • Wound care
  • Adhesion prevention
  • Aesthetics
  • Cardiology
  • Cell/stem cell/biomarker delivery
  • Drug delivery
  • ENT
  • Ophthalmology

Corgel® BioHydrogel is only for research purposes, and not intended for human use.

Ordering Corgel® BioHydrogel
Ordering Corgel® Powder

Publications referencing Corgel®

  • Darr, A., Calabro, A. Synthesis and characterization of tyramine-based hyaluronan hydrogels. J Mater Sci: Mater Med 2009; 20: 33-44
  • Fumoto, H., Takaseya, T., Shiose, A., Saraiva, R.M., Arakawa, Y., Park, M., Rao, S., Dessoffy, R., Chen, J-F., Zhou, Q., Calabro, A., Banbury, M., Fukamachi, K. Mitral Annular Remodeling to Treat Functional Mitral Regurgitation: A Pilot Acute Study in a Canine Model. The Heart Surgery Forum 2010; 13(4): E247-E250
  • Chin, L., Calabro, A., Rodriguez, E.R., Tan, C.D., Walker, E., & Derwin, K.A. J Mater Sci: Mater Med 2011; Printed online May 2011
  • Chin, L., Calabro, A., Walker, E., & Derwin, K.A. Mechanical properties of tyramine substituted-hyaluronan enriched
    fascia extracellular matrix. Journal of Biomedical Materials Research Part A 2012; Printed online January 11, 2012

General information on the FDA’s position on cell/scaffold products

  • McCright, B., et al. Synopsis of the Food and Drug Administration-National Institute of Standards and Technology Co-Sponsored “In Vitro Analyses of Cell/Scaffold Products” Workshop. Tissue Engineering: Part A 2009; 15: 1-6

General information discussing hyaluronan-based hydrogels

  • Hilborn, J. In vivo injectable gels for tissue repair. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 2010; Published online July 21, 2011
  • Jatav, V.S., Singh, H., & Singh, S.K. Recent Trends on Hydrogel in Human Body. International Journal of Research in Pharmaceutical and Biomedical Sciences, 2011; 2(2); 442-447

Corgel®BioHydrogel (TS-NaHy) technology is covered by US patents 6,982,298; 7,368,502; 7,465,766
Cleveland Clinic is a © of The Cleveland Clinic Foundation
Lifecore Biomedical and Corgel are trademarks of Lifecore Biomedical,